4 New Partners Bolster Life Sciences IP Litigation at Stris & Maher

Biotech and pharma executives now have another law firm option for the high-stakes patent fights that determine market exclusivity. The four new partners at Stris & Maher bring more than 100 combined PTAB and reexamination proceedings plus Hatch-Waxman experience on both branded and generic sides, supported by academic backgrounds in biological sciences. For companies facing validity challenges or preparing biosimilar litigation, that scientific fluency can shorten the time from technical analysis to courtroom strategy.

Stris & Maher LLP announced on August 24, 2026 that Mieke Malmberg, Sarah Spires, Steven Hartsell, and Jaime Olin have joined the firm as partners, with Malmberg based in Los Angeles and the other three anchoring a new Dallas office. The announcement, distributed via ACCESS Newswire, is a lateral hiring event that significantly expands the firm's intellectual property and life sciences litigation platform. While the move is self-reported and not independently verified, it reflects a strategic bet on high-stakes patent disputes, particularly in the pharmaceutical and biotechnology sectors.

“

Stris & Maher LLP announced on August 24, 2026 that Mieke Malmberg, Sarah Spires, Steven Hartsell, and Jaime Olin have joined the firm as partners, with Malmberg based in Los Angeles and the other three anchoring a new Dallas office.

According to the firm's announcement, the incoming group has litigated patent cases in the nation's major patent venues, tried high-stakes cases before juries and judges, won appeals before the U.S. Court of Appeals for the Federal Circuit, represented patent owners and challengers in well over 100 inter partes review and ex parte reexamination proceedings, and handled Hatch-Waxman litigation for both branded and generic pharmaceutical companies. This breadth matters because patent litigation has increasingly become a two-front war: district court infringement actions and validity challenges before the Patent Trial and Appeal Board. A team that can coordinate both forums—and has Federal Circuit appellate experience—can shape case strategy more efficiently than one limited to trial work.

The decision to open a Dallas office is particularly notable. Texas has become one of the busiest patent dockets in the country, with the Western and Northern Districts historically attracting large volumes of patent filings. Dallas itself has emerged as a hub for IP litigation, and placing three partners there signals the firm's intent to capture Texas-based clients and reduce local counsel friction. The Northern District of Texas and the Western District of Texas have become among the busiest patent venues in the country. The Western District's Waco division, in particular, attracted a flood of patent filings before recent case assignment changes redistributed cases across the district. Dallas's federal court remains a preferred venue for technology and pharmaceutical companies, and a physical office there can reduce costs and signal commitment to clients. This geographic expansion comes as law firms increasingly view Texas as a critical jurisdiction for patent litigation.

For the legal industry, the move reflects continued consolidation of elite IP practices. Boutique and midsized firms are competing aggressively for a limited pool of lawyers with Federal Circuit and PTAB experience, often recruiting laterals from large firms or government agencies. Stris & Maher's expansion is consistent with a broader pattern in which specialized litigation teams migrate to platforms that can offer more cross-selling opportunities and leaner overhead. Elizabeth Brannen, the firm's Managing Partner and Chair of its Intellectual Property Litigation Practice, called the addition "a significant expansion" and emphasized the group's "unparalleled technical expertise" and "significantly more firepower—particularly in life sciences and Patent Office proceedings."